Non-valvular atrial fibrillation and stroke prevention

Graeme J Hankey
Med J Aust 2001; 174 (5): 234-239.
Published online: 5 March 2001

Position Statement

Non-valvular atrial fibrillation and stroke prevention

Graeme J Hankey, on behalf of the National
Blood Pressure Advisory Committee of the National Heart Foundation*

MJA 2001; 174: 234-239

Abstract - Warfarin versus control - Aspirin versus control - Warfarin versus aspirin - Warfarin combined with aspirin - Warfarin versus other antiplatelet agents - Who to treat and with what? - Who is at high risk of stroke and thromboembolism without treatment? - Who is at high risk of haemorrhage with anticoagulant treatment? - Recommendations for antithrombotic therapy for AF - References - Authors' details

- - More articles on Cardiology and cardiac surgery


  • Atrial fibrillation (AF) affects 5% of people older than 65 years.
  • Among patients with AF, the risk of stroke averages about 5% per year.
  • The risk of stroke increases cumulatively with increasing age, previous transient ischaemic attack or stroke, hypertension, diabetes, impaired left ventricular function and a large left atrium.
  • Management aims to identify and treat the underlying cause, control the ventricular rate, restore and maintain sinus rhythm, and minimise the risk of stroke.
  • Warfarin reduces the risk of stroke by about two-thirds, and aspirin by about one-fifth.
  • The risk of anticoagulant-associated haemorrhage increases with serious concomitant disease, and with poorly controlled hypertension and poorly controlled anticoagulation.
  • All patients with chronic AF should be considered for oral anticoagulant therapy, and the decision based on the balance between the risks of thromboembolism and bleeding.
  • The recommended INR (international normalised ratio) is 2.0-3.0.
  • Treating 1000 "average" AF patients (ie, those with a 5% per year risk of stroke) with warfarin prevents about 30 strokes and causes at least two episodes of major haemorrhage each year. Treating 1000 AF patients with aspirin prevents about 15 strokes each year.

Atrial fibrillation (AF) is a common arrhythmia. Its prevalence increases with age, from about 2% in the general population, to 5% in people older than 65 years, and 10% in people older than 75 years1,2 (E4; level-of-evidence codes are described in Box 13). It may occur as a single episode, a series of recurrent episodes ("paroxysmal" AF), or continuously ("permanent" or "chronic" AF).

Atrial fibrillation is an important arrhythmia because it may signify underlying heart disease, it may cause symptoms of decreased cardiac output (eg, malaise, effort intolerance) or palpitations, and it is associated with an increased risk of systemic thromboembolism and stroke. This risk of stroke averages about 5% per year among all individuals in AF, which is about 5-6 times greater than for people of the same age who are in sinus rhythm (E32).1,2

     The management of AF has four principal objectives:

  1. To confirm and document the arrhythmia;

  2. To identify and treat the underlying cause;

  3. To relieve symptoms of decreased cardiac output by controlling the ventricular rate and restoring and maintaining sinus rhythm; and

  4. To reduce the risk of systemic thromboembolism, particularly stroke.

All patients, except perhaps the very elderly and infirm, should undergo investigation for underlying causes of AF, including thyroid function tests and echocardiography (E4).4

In haemodynamically stable patients, β-blockade, verapamil or diltiazem can be used to control the heart rate (E4). Recent-onset AF reverts spontaneously within 24 hours in at least half of patients (irrespective of whether or not they are taking digoxin) (E33).5

Patients who have been in AF for more than 48 hours should be considered for anticoagulation therapy and strategies to restore and maintain sinus rhythm. Warfarin should be administered for three weeks before cardioversion is attempted.6 If cardioversion can not be postponed for three weeks, the patient should undergo anticoagulation therapy with intravenous heparin and warfarin,7 and be considered for transoesophageal echocardiography (TOE) (E32). Cardioversion can probably be undertaken safely (with limited risk of stroke) if TOE excludes left atrial and appendage thrombus (and the patient is treated with heparin and warfarin) (E2).8,9 However, if transoesophageal echocardiography identifies left atrial and appendage thrombus, then cardioversion is contraindicated until the patient has been anticoagulated for at least three weeks (E4).

The relative merits of cardioversion by electrical shock and medical therapy have been discussed recently.4,10 Direct current cardioversion has never been subjected to a randomised trial, but appears to be the most effective method of restoring sinus rhythm. Its main disadvantage is the need for general anaesthesia. Digoxin and verapamil are ineffective for converting AF to sinus rhythm. Flecainide or sotalol are the preferred medical therapies in younger patients without structural heart disease, and amiodarone in older patients (E2).11 The chances of successful cardioversion are greater if the AF is of recent onset and the left atrial size is normal (E33).12

After successful cardioversion, warfarin therapy should be continued for at least four weeks to prevent clot formation in the "stunned" left atrium (E33).13,14 Antiarrhythmic drug therapy should also be continued to prevent recurrent AF, but this still occurs in 40%-50% of patients after 12 months' follow-up despite drug therapy. If the patient has a low risk of recurrence of AF (eg, "lone" AF) and remains in sinus rhythm for one month after cardioversion, anticoagulation therapy with warfarin can be ceased (E4). In patients at higher risk of recurrence (Box 2), it may be more appropriate to continue warfarin therapy for longer or indefinitely (E4).

For patients who are elderly (in whom AF is usually chronic and antiarrhythmic drug therapy may be risky) or have asymptomatic chronic AF, it is often reasonable to avoid attempted cardioversion, accept the AF and aim for adequate ventricular rate control (digoxin combined with β-blockade, verapamil or diltiazem) and long term anticoagulation therapy (E4). The results of clinical trials in patients with asymptomatic AF (of rate control and antithrombotic therapy versus attempted cardioversion and maintenance of sinus rhythm to avoid warfarin) are awaited.

Strategies for reducing the risk of stroke and systemic thromboembolism in patients with AF have been studied in several randomised controlled trials over the past decade.15-25

Warfarin versus control

Primary prevention

Five large randomised controlled primary prevention trials have shown that, in people with chronic non-valvular AF, warfarin reduced the risk of stroke by about two-thirds (68%; 95% CI, 50%-79%; P < 0.001), from about 4.5% to 1.4% per year overall, with little increase in frequency of major bleeding (warfarin, 1.2%; control, 1.0%), or intracranial haemorrhage (warfarin, 0.3% per year; control, 0.1% per year) (E1).15-19,26 This means that warfarin will prevent about 30 strokes per 1000 patient-years of treatment at a cost of at least two serious bleeding episodes per 1000 patients treated for one year. It must be stressed, however, that this acceptable rate of bleeding was achieved in patients who were carefully selected, screened and closely followed; 53%-93% of eligible patients with AF were not included in the trials because of an increased risk of bleeding. Exclusion criteria included old age (> 75 years), serious illness (liver, kidney, brain or malignant disease), alcoholism, fall risk (eg, syncope), forgetfulness, non-steroidal anti-inflammatory drug therapy, and uncontrolled hypertension.

Secondary prevention

One secondary prevention trial (the European Atrial Fibrillation Trial [EAFT]) showed that, in people with chronic non-valvular AF and symptoms of previous transient ischaemic attack (TIA) or stroke, who have a risk of stroke of 12% per year, warfarin therapy (target INR, 2.5-4.0) reduced the risk of stroke by about two-thirds (66%; 95% CI, 53%-80%), to 4% per year (E2).20 The annual incidence of major bleeding complications was 2.8% in the anticoagulant group and 0.7% in the placebo group. No intracranial bleeds were identified in patients assigned to warfarin. Thus, warfarin prevents about 80 strokes per 1000 patient-years in patients who have had a TIA or stroke and who are in AF, at a cost of at least 20 serious bleeding episodes per 1000 patients treated for one year.

The timing of anticoagulation therapy after recent ischaemic stroke depends on the risk of recurrent thromboembolism (Box 2) and the risk of haemorrhagic transformation of the brain infarct (which is higher within the first two weeks and in patients with large brain infarcts and uncontrolled hypertension [E32]27). Common empirical practice is to treat patients with fibrillating acute ischaemic stroke immediately with aspirin (300 mg daily) and then, depending on the above factors, begin warfarin (5 mg daily) between days three and 14 after stroke onset, aiming to achieve an INR of 2.0.28 However, randomised trials comparing aspirin with heparin during the first two weeks of acute ischaemic stroke among patients in AF show no benefit from early anticoagulation, because any net gains from reduction in recurrent ischaemic stroke are offset by the excess hazards of haemorrhagic stroke (E1).29,30

Aspirin versus control

Three primary prevention and three secondary prevention trials have shown that, in people with AF, aspirin reduced the incidence of stroke by 22% (95% CI, 2%-38%), from 5.2% (placebo) to 3.7% (aspirin) per year for primary prevention (absolute risk reduction: 1.5% per year), and from 12.9% (placebo) to 10.4% (aspirin) per year for secondary prevention (absolute risk reduction, 2.5% per year) (E1).31

Aspirin was not associated with any significant excess of intracranial haemorrhage (aspirin, 0.16%; control, 0.13%) or major extracranial bleeding (aspirin, 0.5%; control, 0.6%) (E1).31 This means that aspirin might prevent about 10 to 20 strokes per 1000 patient-years of treatment, depending on the type of patient treated and their baseline risk of stroke, with little risk of major bleeding.

A speculative interpretation of these data is that, in patients with AF, aspirin prevents strokes due to atherothromboembolism, but not cardiogenic embolism. This interpretation is based on the magnitude of the effect (a 20% relative risk reduction), which is very similar to the effect of aspirin in patients with symptomatic atherothromboembolism of the brain, heart and limbs.32 Whether aspirin combined with adjusted-dose warfarin would be safe and more effective (in preventing both atherothrombotic and cardiogenic strokes) than warfarin alone in patients with AF remains unknown.33

Warfarin versus aspirin

The relative benefits and risks of warfarin and aspirin have been studied in three trials,15,20,21 all of which showed that warfarin was associated with half the risk of stroke compared with aspirin (47% relative risk reduction; 95% CI, 28%-61%; P < 0.01) (E1).26

Warfarin combined with aspirin

For patients with AF who are at high risk of stroke, adding aspirin (325 mg daily) to low-intensity, fixed-dose warfarin, adjusted to an INR of 1.2-1.5, was not as effective in preventing stroke or systemic thromboembolism as standard adjusted-dose warfarin therapy, maintaining an INR of 2.0-3.0 (event rates, 7.9% per year v. 1.9% per year, respectively; P < 0.0001), and there is no difference in the rates of major bleeding (E2).22 Three subsequent trials also suggested that adjusted-dose warfarin (INR, 2.0-3.0) was superior to low-intensity anticoagulant therapy or an aspirin- anticoagulation regimen (E1).23-25

Warfarin versus other antiplatelet agents

An Italian study reported that a new antiplatelet agent, indobufen (100-200 mg twice daily), was as effective as adjusted-dose warfarin (INR, 2.0-3.5) in preventing stroke, systemic embolism, myocardial infarction or vascular death in 916 patients with non-valvular AF and recent (within 15 days) TIA or non-disabling ischaemic stroke (E2).34 The 12-month event rates were 10% in the warfarin group and 12% in the indobufen group (P = 0.47). However, the number of patients and outcome events were quite small, follow-up was short, and it is possible that a true difference was not detected.

Future studies are planned to evaluate the safety and effectiveness of other, newer antiplatelet agents (such as clopidogrel, oral glycoprotein IIb/IIIa receptor inhibitors, and oral thrombin inhibitors) and combination antiplatelet therapies (such as aspirin-ticlopidine, aspirin-clopidogrel, and aspirin-dipyridamole) as strategies of thromboprophylaxis in AF.

Who to treat and with what?

Not all patients with AF benefit from thromboprophylactic treatment. The decision to treat depends on the balance between the risk of thromboemboli without treatment and the risks of thromboemboli and haemorrhage with treatment in each patient, as well as the patient's willingness to accept the potential risks, costs, and inconvenience of treatment in order to possibly benefit. The current profile of individual risk of thromboembolism and bleeding complications (see below) remains imprecise and continues to be refined as new data emerge.7

Who is at high risk of stroke and thromboembolism without treatment?

The important independent prognostic factors for an increased risk of stroke among individuals with AF are increasing age, a history of previous TIA or stroke, hypertension, diabetes mellitus, and transthoracic echocardiographic evidence of moderate to severe left ventricular systolic dysfunction (E1).7,26,35-37 Echocardiographic evidence of left atrial enlargement (E2) and left atrial spontaneous echo densities ("smoke"), possibly indicative of stasis of blood, are also significant risk factors for stroke36-39 (E33).

These risk factors are cumulative: for people younger than 65 years with no risk factors the untreated annual risk of stroke is about 1%, whereas with one or more risk factors it is about 5%; for people aged 65-75 years with no risk factors the annual risk of stroke is about 4%, and with one or more risk factors it is about 6% per year; and for people older than 75 years with no risk factors the risk of stroke is about 3%-4%, whereas with one or more risk factors it is about 8% (see Box 2) (E1).7,26

Who is at high risk of haemorrhage with anticoagulant treatment?

The major risk factors for anticoagulant-associated intracranial haemorrhage include fragile intracranial blood vessels (previous symptomatic cerebrovascular disease, computed tomography brain scan evidence of small vessel disease ["leukoaraioisis"]), high blood pressure (poorly controlled hypertension), and excessive anticoagulation (INR, > 3.5) or factors predisposing to it, such as confusion, dementia, inadequate anticoagulant monitoring, alcoholic liver disease, and a tendency to falls (E2).40,41 Increasing age is a risk factor for all of these risk factors, and is thus a potent risk factor for anticoagulant-associated haemorrhage. Among a subgroup of patients in the Stroke Prevention in Atrial Fibrillation (SPAF) II trial (mean age, 80 years), the rate of intracranial haemorrhage was as high as 1.8% per year in those allocated to warfarin therapy (target INR, 2.0-4.5) and 0.8% among those who were assigned to aspirin (E2).21 Although the target INR in this study was higher than currently recommended (INR, 2.0-3.0), these data suggest that the low rate of intracranial haemorrhage documented in the five primary prevention AF trials15-19 may not apply to very elderly individuals (who were not well represented in many of these trials -- the mean age of the patients studied in the AF trials was 69 years, and only about a quarter were older than 75 years).

Recommendations for antithrombotic therapy for AF

Current practice necessitates individualisation of therapy after an integrated clinical assessment that evaluates thromboembolic risk due to AF, other potential indications for anticoagulant therapy, risk of haemorrhage, and non-medical factors relating to compliance, capacity to have the INR monitored at least monthly, gait instability, risk of other trauma, and patient values and preferences.42,43 Decision analysis can also be useful.44

The role of transthoracic echocardiography (TTE), in addition to excluding structural heart disease in all patients who first present with AF, is to further refine stroke risk in the small group of patients with a low risk of stroke according to clinical factors. Although TOE is more sensitive in detecting left atrial thrombus and spontaneous echo contrast, which are markers for increased risk of thromboembolism,36-39 it is more invasive and is usually only required to improve risk stratification among individuals with a relative contraindication to warfarin or in whom TTE is inadequate.

The choices of thromboprophylactic agents for atrial fibrillation include warfarin, which is the most effective but also the most risky treatment, and aspirin, which is less effective than warfarin but safer (E1). The combination of aspirin and low dose warfarin is no more effective than aspirin alone (E1).22,23 The most appropriate treatment regimen is one in which patients at high risk of stroke and low risk of haemorrhage are treated with warfarin, and patients at low risk of stroke or high risk of haemorrhage are treated with aspirin.

Who not to treat

Individuals with AF who are aged less than 60 years and have no evidence of any concurrent heart disease have a very low risk of a thromboembolic event (about 0.6% per year).45 The potential benefits of aspirin in these patients (which may reduce the risk of stroke by 0.12% per year [20% of 0.6%]) may be offset by an equal potential risk of aspirin-associated haemorrhagic stroke of 0.12%.46

Who to treat with aspirin

Aspirin is indicated for individuals in AF who are at fairly low absolute risk of stroke, such as those without any of the independent thromboembolic risk factors listed above, or those at risk of an anticoagulant-related haemorrhage which exceeds the risk of stroke (more than 1% per year) (E1). For some people, such as the elderly and those with hypertension, whose risks of stroke and haemorrhage are both high, the treatment decision can be difficult, and may be determined ultimately by the patient's preferences.42,43

Patients taking aspirin should be monitored over time and their treatment changed to warfarin if risk factors emerge; this occurs in 10%-15% of patients being treated with aspirin per year.21

Who to treat with warfarin

Warfarin is indicated for individuals with chronic AF who are at high absolute risk of stroke (> 4% per year), such as those with any of the independent thromboembolic risk factors listed above, and a lower risk of haemorrhage (E1) (see Box 2).

Similarly, anticoagulant therapy should also be considered in patients with paroxysmal AF, again depending on the thromboembolic risk factors (Box 2) as well as the frequency and duration of the paroxysms. Although clinical trial evidence suggests the stroke rate of patients with paroxysmal AF is similar to that of patients with chronic AF,26 the trials did not specifically examine the benefits of antithrombotic therapy in patients with paroxysmal AF. Furthermore, the range of thromboembolic risk in such patients is likely to be extremely wide, from very low for patients who have one short paroxysm once a year to considerably higher for patients who have daily lengthy paroxysms.

What is the optimal target INR?

The intensity of oral anticoagulant therapy that provides the best balance between the prevention of thromboembolism and the occurrence of bleeding complications appears to be an INR of between 2.0 and 3.0, but may be lower (INR, 1.8 to 2.0) in patients at greater risk of bleeding (eg, the elderly), and may be higher in patients at greater risk of thromboembolism, such as those with prosthetic heart valves [INR, 3.0-4.0]) (E32).47,48

It is important to emphasise that, in people in whom anticoagulant therapy is indicated, the risk of stroke increases substantially when the INR falls below 2.0. Patients with an INR of 1.7 have twice the odds of stroke (95% CI, 1.6-2.4 times), and those with an INR of 1.5 have 3.3 times the odds of stroke (95% CI, 2.4-4.6 times) as those with an INR of 2.047 (E32).

What if warfarin therapy needs to be ceased?

When cessation of warfarin therapy is required because of other (usually surgical) procedures, it is necessary to stratify the invasiveness of the procedure (minimal versus major) and the short-term risk of thromboembolism. Warfarin can be discontinued for five days before a major procedure and continued at a decreased dose for a minor procedure. Therapy should be reinstituted as soon as possible after invasive procedures. Patients at high risk of thromboembolism (eg, severe mitral stenosis, mechanical mitral prosthesis, left ventricular dysfunction) should be admitted to hospital early for intravenous administration of heparin during warfarin cessation.


  1. Lake FR, Cullen KJ, de Klerk NH, et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-326.
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
  3. National Health and Medical Research Council. A guide to the development, implementation, and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
  4. Kilborn MJ. Atrial fibrillation. Med J Aust 1999; 170: 498-504.
  5. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987; 106: 503-506.
  6. Stoddard MF. Risk of thromboembolism in new onset or transient atrial fibrillation. Prog Cardiovasc Dis 1996; 39: 69-80.
  7. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114 (5 Suppl): 579S-589S.
  8. Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by transesophageal echocardiography: The ACUTE Pilot Study. A randomised, controlled trial. Ann Intern Med 1997; 126: 200-209.
  9. Bashir M, Grimm RA, Jaber WA, et al. Elderly patients do not have an excessive risk for complications or recurrence following transoesophageal echocardiography-guided cardioversion of atrial arrhythmias: results from the ACUTE registry. J Am Coll Cardiol 2000; 35 (Suppl A): 119A (abstract no. 1097-73).
  10. Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and anti-arrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999; 130: 625-636.
  11. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
  12. Resnekov L. Present status of electroversion in the management of cardiac dysrhythmias. Circulation 1973; 47: 1356-1363.
  13. Lown B, Perlroth MG, Kaidbey S, et al. "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963; 269: 325-331.
  14. Manning WJ, Silverman DI, Gordon SPF, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750-755.
  15. Petersen P, Boysen G, Godfredsen J, et al. Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1988; i: 175-179.
  16. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-1511.
  17. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-539.
  18. Connolly SJ, Laupacis A, Gent M, et al, for the CAFA Study Coinvestigators. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355.
  19. Ezekowitz MD, Bridgers SL, James KE, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) Investigators. Warfarin in the prevention of stroke associated with atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
  20. Secondary prevention in nonrheumatic atrial fibrillation and transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-1262.
  21. Warfarin versus aspirin for the prevention of thrombo-embolism in atrial fibrillation. Stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-691.
  22. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
  23. Gullov AL, Koefoed BG, Petersen P, et al. Mini-dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation Aspirin and Anticoagulation Study (AFASAK 2). Arch Intern Med 1998; 158: 1513-1521.
  24. Vermeer F, Langenberg M, Hellemons BS, et al. Primary prevention of arterial thrombo-embolism in non-rheumatic atrial fibrillation: results of the PATAF study. Eur Heart J 1998; 19 (Abstract Suppl): 154.
  25. Pengo V, Zasso A, Barberi F, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998; 82: 433-437.
  26. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-1457.
  27. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial haemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477.
  28. Gallus AS, Baker RI, Chong BH, et al, on behalf of the Australasian Society of Thrombosis and Haemostasis. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172: 600-605.
  29. Berge E, Abdelnoor M, Nakstad PH, Sandset PM, on behalf of the HAEST Study Group. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet 2000; 355: 1205-1210.
  30. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-1581.
  31. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131: 492-501.
  32. Collaborative overview of randomised trials of anti platelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
  33. Peverill RE. Warfarin or aspirin: both or others? Med J Aust 1999; 171: 321-326.
  34. Morocutti C, Amabile G, Fattapposta F, et al, for the SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28: 1015-1021.
  35. Predictors of thromboembolism in atrial fibrillation: clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 1-5.
  36. Predictors of thromboembolism in atrial fibrillation: echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 6-12.
  37. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316-1320.
  38. Fatkin D, Feneley M. Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echo contrast. Prog Cardiovasc Dis 1996; 39: 57-68.
  39. Jones EF, Calafiore P, McNeil J, et al. Atrial fibrillation with left atrial spontaneous contrast detected by transoesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996; 78: 425-429.
  40. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156: 409-416.
  41. A randomised trial of anticoagulants versus aspirin after cerebral ischaemia of presumed arterial origin. The Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) Study Group. Ann Neurol 1997, 42: 857-865.
  42. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G. Warfarin for atrial fibrillation: the patient perspective. Arch Intern Med 1996; 156: 1841-1848.
  43. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083-1091.
  44. Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-962.
  45. Kopecky SL, Gersh BJ, McGoon MD. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987; 317: 669-674.
  46. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. A meta-analysis of randomised controlled trials. JAMA 1998; 280: 1930-1935.
  47. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
  48. Cannegieter SC, Rosendal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.


Background and evidence basis of recommendations

The National Heart Foundation (NHF) Consensus Guidelines for Non-valvular Atrial Fibrillation and Stroke Prevention were written by Clinical Associate Professor Graeme J Hankey on behalf of the National Blood Pressure Advisory Committee of the NHF, which comprises Professor L Wing (chair), Dr A Boyden, Dr A Dart, Dr K Duggan, Clinical Associate Professor G Hankey, Dr M Nelson, Professor I Puddey, Dr M Stowasser, and Dr J Vial. The draft guidelines were circulated for comment to the above members of the committee, who have clinical and research expertise or interests in hypertension, atrial fibrillation, and stroke prevention. Comment was also sought from the Medical Director of the Heart Foundation, Professor Andrew Tonkin. All comments were incorporated into the final document, which was ratified by the Heart Foundation's Cardiovascular Health Advisory Committee. All available evidence from controlled experimental and observational studies was combined with clinical experience to provide recommendations according to the National Health and Medical Research Council Quality of Evidence ratings.3

Authors' details

National Heart Foundation of Australia, Melbourne, VIC.
Graeme J Hankey, MD, FRACP, Consultant Neurologist and Head of Stroke Unit, Royal Perth Hospital, Perth, WA, and Clinical Associate Professor, Department of Medicine, University of Western Australia.

Reprints will not be available from the author.
Correspondence: Clinical Associate Professor G J Hankey, Stroke Unit, Royal Perth Hospital, Wellington Street, Perth, WA 6001.

* L Wing (chair), A Boyden, A Dart, K Duggan, M Nelson, I Puddey, M Stowasser, J Vial


1: Level-of-evidence codes
Evidence for the statements made in this article is graded according to the NHMRC system3 for assessing the level of evidence:
E1 Level I Evidence obtained from a systematic review of all relevant randomised controlled trials.
E2 Level II Evidence obtained from at least one properly designed randomised controlled trial.
E31 Level III-1 Evidence obtained from well-designed pseudo-randomised controlled trials (alternate allocation or some other method).
E32 Level III-2 Evidence obtained from comparative studies with concurrent controls and allocation not randomised (cohort studies), case-control studies, or interrupted time series without a parallel control group.
E33 Level III-3 Evidence obtained from comparative studies with historical control, two or more single-arm studies, or interrupted time series without a parallel control group.
E4 Level IV Evidence obtained from case-series, either post-test, or pretest and post-test.
Back to text
2: Risk stratification and prophylaxis in atrial fibrillation
High risk (6%-12% per year risk of stroke)
  • Age >65 years and hypertension or diabetes
  • Previous transient ischaemic attack (TIA) or stroke
  • Valvular heart disease o Heart failure
  • Recent myocardial infarction
  • Impaired left ventricular function on echocardiography
  • Thyroid disease o Left atrial thrombus or left atrial spontaneous echo contrast (TOE done on basis of clinical suspicion)
Treatment: Warfarin (target INR 2.0-3.0) if possible and not contraindicated.
Moderate risk (2%-5% per year risk of stroke)
  • Age 65 years and hypertension or diabetes
  • Age >65 years and not in high risk group
Treatment: Warfarin (target INR 2.0-3.0) or aspirin 75-300mg daily, depending on individual case and echocardiography findings.
Low risk (≤1% per year risk of stroke)
  • Age 65 and no hypertension, diabetes, TIA, stroke, or other clinical risk factors
Treatment: None, or aspirin 75-300mg daily.
Back to text
  • Graeme J Hankey



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.